Market Access, EBMA Consulting, Melegnano, ITALY Aim: Regional and hospital payers increasingly require analyses assessing the cost-benefit profile of new drugs. This analysis evaluates the cost profile in Nordic countries of nano albumin-bound paclitaxel (nab-paclitaxel [nab-P]) in pancreatic cancer vs other drugs per gained month in OS and PFS in high-unmet need solid tumour indications. Methods: Trial data on solid tumour therapies (comparator, treatment duration, PFS, OS) was retrieved from the European Medicine Agency (EMA) website. Total drug costs were calculated from ex-manufacturer prices without local discounts, using minimization of wastage and costs, and multiplying each drug cost by its maximum number of cycles or until disease progression, according to posology indications. Costs per month of OS and PFS achieved (dividing total drug costs by OS and PFS months, respectively) were evaluated for a selection of drugs: (1) trials for first-line metastatic cancer or noncurable treatment intention patients; (2) approved by EMA after 2000; (3) indicated in high-unmet need tumours (defined as OS for trial comparator ≤ 12 mo). Results: Results for the OS analysis are shown on the table:In all countries, a good correlation between costs per OS month and relative benefit vs trial comparator was observed. Similar correlation was found for the PFS analysis. Conclusions: The most recently approved drug, nab-P in pancreatic cancer, showed a similar cost per OS or PFS month ratio compared with other drugs for high-unmet need solid tumours.
